Selected research
Industry Research
Hepatic Encephalopathy Drugs Industry Research Report 2026
Market perspective
The global Hepatic Encephalopathy Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Hepatic Encephalopathy Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Hepatic Encephalopathy Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Hepatic Encephalopathy Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Hepatic Encephalopathy Drugs include Umecrine Cognition, Norgine, Mallinckrodt, Lupin, Kannalife Sciences, Kaleido Biosciences, Ferring Pharmaceuticals, Cosmo Pharmaceuticals and Bausch Health, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Hepatic Encephalopathy Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (tons), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/tons) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Hepatic Encephalopathy Drugs Market by Company
Umecrine Cognition
Norgine
Mallinckrodt
Lupin
Kannalife Sciences
Kaleido Biosciences
Ferring Pharmaceuticals
Cosmo Pharmaceuticals
Bausch Health
ASKA Pharmaceutical
Hepatic Encephalopathy Drugs Segment by Type
Injection
Oral
Hepatic Encephalopathy Drugs Segment by Application
Hospital Pharmacies
Online Pharmacies
Retail Pharmacies
Hepatic Encephalopathy Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hepatic Encephalopathy Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Hepatic Encephalopathy Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hepatic Encephalopathy Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Hepatic Encephalopathy Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Hepatic Encephalopathy Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Hepatic Encephalopathy Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Injection
- Oral
Applications
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
Companies covered
- Umecrine Cognition
- Norgine
- Mallinckrodt
- Lupin
- Kannalife Sciences
- Kaleido Biosciences
- Ferring Pharmaceuticals
- Cosmo Pharmaceuticals
- Bausch Health
- ASKA Pharmaceutical
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Hepatic Encephalopathy Drugs Market Size (2021-2032)
- 2.2.2 Global Hepatic Encephalopathy Drugs Sales (2021-2032)
- 2.2.3 Global Hepatic Encephalopathy Drugs Market Average Price (2021-2032)
- 2.3 Hepatic Encephalopathy Drugs by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Injection
- 2.3.3 Oral
- 2.4 Hepatic Encephalopathy Drugs by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital Pharmacies
- 2.4.3 Online Pharmacies
- 2.4.4 Retail Pharmacies
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Hepatic Encephalopathy Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Hepatic Encephalopathy Drugs Sales (tons) of Manufacturers (2021-2026)
- 3.3 Global Hepatic Encephalopathy Drugs Revenue of Manufacturers (2021-2026)
- 3.4 Global Hepatic Encephalopathy Drugs Average Price by Manufacturers (2021-2026)
- 3.5 Global Hepatic Encephalopathy Drugs Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Hepatic Encephalopathy Drugs, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Hepatic Encephalopathy Drugs, Product Type & Application
- 3.8 Global Manufacturers of Hepatic Encephalopathy Drugs, Established Date
- 3.9 Global Hepatic Encephalopathy Drugs Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Umecrine Cognition
- 4.1.1 Umecrine Cognition Company Information
- 4.1.2 Umecrine Cognition Business Overview
- 4.1.3 Umecrine Cognition Hepatic Encephalopathy Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Umecrine Cognition Hepatic Encephalopathy Drugs Product Portfolio
- 4.1.5 Umecrine Cognition Recent Developments
- 4.2 Norgine
- 4.2.1 Norgine Company Information
- 4.2.2 Norgine Business Overview
- 4.2.3 Norgine Hepatic Encephalopathy Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Norgine Hepatic Encephalopathy Drugs Product Portfolio
- 4.2.5 Norgine Recent Developments
- 4.3 Mallinckrodt
- 4.3.1 Mallinckrodt Company Information
- 4.3.2 Mallinckrodt Business Overview
- 4.3.3 Mallinckrodt Hepatic Encephalopathy Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Mallinckrodt Hepatic Encephalopathy Drugs Product Portfolio
- 4.3.5 Mallinckrodt Recent Developments
- 4.4 Lupin
- 4.4.1 Lupin Company Information
- 4.4.2 Lupin Business Overview
- 4.4.3 Lupin Hepatic Encephalopathy Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Lupin Hepatic Encephalopathy Drugs Product Portfolio
- 4.4.5 Lupin Recent Developments
- 4.5 Kannalife Sciences
- 4.5.1 Kannalife Sciences Company Information
- 4.5.2 Kannalife Sciences Business Overview
- 4.5.3 Kannalife Sciences Hepatic Encephalopathy Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Kannalife Sciences Hepatic Encephalopathy Drugs Product Portfolio
- 4.5.5 Kannalife Sciences Recent Developments
- 4.6 Kaleido Biosciences
- 4.6.1 Kaleido Biosciences Company Information
- 4.6.2 Kaleido Biosciences Business Overview
- 4.6.3 Kaleido Biosciences Hepatic Encephalopathy Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Kaleido Biosciences Hepatic Encephalopathy Drugs Product Portfolio
- 4.6.5 Kaleido Biosciences Recent Developments
- 4.7 Ferring Pharmaceuticals
- 4.7.1 Ferring Pharmaceuticals Company Information
- 4.7.2 Ferring Pharmaceuticals Business Overview
- 4.7.3 Ferring Pharmaceuticals Hepatic Encephalopathy Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Ferring Pharmaceuticals Hepatic Encephalopathy Drugs Product Portfolio
- 4.7.5 Ferring Pharmaceuticals Recent Developments
- 4.8 Cosmo Pharmaceuticals
- 4.8.1 Cosmo Pharmaceuticals Company Information
- 4.8.2 Cosmo Pharmaceuticals Business Overview
- 4.8.3 Cosmo Pharmaceuticals Hepatic Encephalopathy Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Cosmo Pharmaceuticals Hepatic Encephalopathy Drugs Product Portfolio
- 4.8.5 Cosmo Pharmaceuticals Recent Developments
- 4.9 Bausch Health
- 4.9.1 Bausch Health Company Information
- 4.9.2 Bausch Health Business Overview
- 4.9.3 Bausch Health Hepatic Encephalopathy Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Bausch Health Hepatic Encephalopathy Drugs Product Portfolio
- 4.9.5 Bausch Health Recent Developments
- 4.10 ASKA Pharmaceutical
- 4.10.1 ASKA Pharmaceutical Company Information
- 4.10.2 ASKA Pharmaceutical Business Overview
- 4.10.3 ASKA Pharmaceutical Hepatic Encephalopathy Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 ASKA Pharmaceutical Hepatic Encephalopathy Drugs Product Portfolio
- 4.10.5 ASKA Pharmaceutical Recent Developments
5 Global Hepatic Encephalopathy Drugs Market Scenario by Region
- 5.1 Global Hepatic Encephalopathy Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Hepatic Encephalopathy Drugs Sales by Region: 2021-2032
- 5.2.1 Global Hepatic Encephalopathy Drugs Sales by Region: 2021-2026
- 5.2.2 Global Hepatic Encephalopathy Drugs Sales by Region: 2027-2032
- 5.3 Global Hepatic Encephalopathy Drugs Revenue by Region: 2021-2032
- 5.3.1 Global Hepatic Encephalopathy Drugs Revenue by Region: 2021-2026
- 5.3.2 Global Hepatic Encephalopathy Drugs Revenue by Region: 2027-2032
- 5.4 North America Hepatic Encephalopathy Drugs Market Facts & Figures by Country
- 5.4.1 North America Hepatic Encephalopathy Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Hepatic Encephalopathy Drugs Sales by Country (2021-2032)
- 5.4.3 North America Hepatic Encephalopathy Drugs Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Hepatic Encephalopathy Drugs Market Facts & Figures by Country
- 5.5.1 Europe Hepatic Encephalopathy Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Hepatic Encephalopathy Drugs Sales by Country (2021-2032)
- 5.5.3 Europe Hepatic Encephalopathy Drugs Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Hepatic Encephalopathy Drugs Market Facts & Figures by Country
- 5.6.1 Asia Pacific Hepatic Encephalopathy Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Hepatic Encephalopathy Drugs Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Hepatic Encephalopathy Drugs Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Hepatic Encephalopathy Drugs Market Facts & Figures by Country
- 5.7.1 South America Hepatic Encephalopathy Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Hepatic Encephalopathy Drugs Sales by Country (2021-2032)
- 5.7.3 South America Hepatic Encephalopathy Drugs Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Hepatic Encephalopathy Drugs Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Hepatic Encephalopathy Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Hepatic Encephalopathy Drugs Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Hepatic Encephalopathy Drugs Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Hepatic Encephalopathy Drugs Sales by Type (2021-2032)
- 6.1.1 Global Hepatic Encephalopathy Drugs Sales by Type (2021-2032) & (tons)
- 6.1.2 Global Hepatic Encephalopathy Drugs Sales Market Share by Type (2021-2032)
- 6.2 Global Hepatic Encephalopathy Drugs Revenue by Type (2021-2032)
- 6.2.1 Global Hepatic Encephalopathy Drugs Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Hepatic Encephalopathy Drugs Revenue Market Share by Type (2021-2032)
- 6.3 Global Hepatic Encephalopathy Drugs Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Hepatic Encephalopathy Drugs Sales by Application (2021-2032)
- 7.1.1 Global Hepatic Encephalopathy Drugs Sales by Application (2021-2032) & (tons)
- 7.1.2 Global Hepatic Encephalopathy Drugs Sales Market Share by Application (2021-2032)
- 7.2 Global Hepatic Encephalopathy Drugs Revenue by Application (2021-2032)
- 7.2.1 Global Hepatic Encephalopathy Drugs Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Hepatic Encephalopathy Drugs Revenue Market Share by Application (2021-2032)
- 7.3 Global Hepatic Encephalopathy Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Hepatic Encephalopathy Drugs Value Chain Analysis
- 8.1.1 Hepatic Encephalopathy Drugs Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Hepatic Encephalopathy Drugs Production Mode & Process
- 8.2 Hepatic Encephalopathy Drugs Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Hepatic Encephalopathy Drugs Distributors
- 8.2.3 Hepatic Encephalopathy Drugs Customers
9 Global Hepatic Encephalopathy Drugs Analyzing Market Dynamics
- 9.1 Hepatic Encephalopathy Drugs Industry Trends
- 9.2 Hepatic Encephalopathy Drugs Industry Drivers
- 9.3 Hepatic Encephalopathy Drugs Industry Opportunities and Challenges
- 9.4 Hepatic Encephalopathy Drugs Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst